Ticker Details
PTC Therapeutics, Inc. PTC Therapeutics Inc is a biopharmaceutical company. It is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
IPO Date:	June 20, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.86B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.87 | 2.62%
Avg Daily Range (30 D):	$0.97 | 1.46%
Avg Daily Range (90 D):	$1.05 | 1.45%

Institutional Daily Volume
Avg Daily Volume:	.73M
Avg Daily Volume (30 D):	.75M
Avg Daily Volume (90 D):	.85M

Trade Size
Avg Trade Size (Sh.):	87
Avg Trade Size (Sh.) (30 D):	47
Avg Trade Size (Sh.) (90 D):	50

Institutional Trades
Total Institutional Trades:	7,815
Avg Institutional Trade:	$2.87M
Avg Institutional Trade (30 D):	$6.05M
Avg Institutional Trade (90 D):	$6.38M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.93M
Avg Closing Trade (30 D):	$16.11M
Avg Closing Trade (90 D):	$18.16M
Avg Closing Volume:	112.86K

News

Dec 31, 2025 @ 3:47 PM What's Going On With Royalty Pharma Stock Wednesda... Source: Vandana Singh

Dec 29, 2025 @ 9:40 PM Royalty Pharma Acquires Remaining Royalty Interest... Source: Globe Newswire

Sep 5, 2025 @ 12:35 PM Here's Why Shares in PTC Therapeutics Soared This ... Source: Lee Samaha

Jul 17, 2025 @ 5:00 AM Novartis reports strong Q2 with double-digit sales... Source: Novartis

Jun 2, 2025 @ 5:55 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$8.58	$-1.82	$8.58
Diluted EPS	$7.78	$-1.67	$7.78
Revenue	$1.73B	$164.68M	$1.73B
Gross Profit
Net Income / Loss	$682.64M	$-134.97M	$682.64M
Operating Income / Loss	$866.94M	$-71.35M	$866.94M
Cost of Revenue
Net Cash Flow	$180.31M	$302.24M	$180.31M
PE Ratio	8.83